Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nykode Therapeutics ASFRA:5VB -0.40%48 Cash Ratio is 11.74 as of Mar. 2026, which is 30% above its 10-year median of 9.00. GuruFocus rates FRA:5VB with a GF Score™ of 48/100 and a GF Value™ of €0.48 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, Nykode Therapeutics AS ranks better than 84.03% on this metric.
Nykode Therapeutics AS has a Cash Ratio of 11.74. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Nykode Therapeutics AS's Cash Ratio or its related term are showing as below:
FRA:5VB'
s Cash Ratio Range Over the Past 10 Years
Min: 5.28 Med: 9 Max: 20.32
Current: 11.74
During the past 9 years, Nykode Therapeutics AS's highest Cash Ratio was 20.32. The lowest was 5.28. And the median was 9.00.
FRA:5VB's Cash Ratio is ranked better than 84.03% of 1384
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:5VB: 11.74
Nykode Therapeutics AS (FRA:5VB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VB vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (FRA:5VB) has a Cash Ratio of 11.74 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nykode Therapeutics AS and its competitors. This is 30% above median its historical median of 9.00. Over the past decade, Nykode Therapeutics AS's Cash Ratio has ranged from 5.28 to 20.32. According to the industry distribution chart, Nykode Therapeutics AS ranks #221 out of 1384 companies in the Biotechnology industry, placing it in the top 16%.
Is Nykode Therapeutics AS's Cash Ratio too high?
Nykode Therapeutics AS's current Cash Ratio of 11.74 is 30% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 5.28 to a high of 20.32. The Biotechnology industry median Cash Ratio is 2.93. Nykode Therapeutics AS's value of 11.74 is 300.7% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #221 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #221 out of 1384 companies for Cash Ratio. This places Nykode Therapeutics AS in the top 16% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Nykode Therapeutics AS's value of 11.74 is 300.7% above this benchmark. Historically, Nykode Therapeutics AS's own Cash Ratio has ranged from 5.28 to 20.32 over the past decade. While the company's 10-year median is 9.00 vs. the industry median of 2.93, Nykode Therapeutics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Cash Ratio of 11.74 is 300.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Cash Ratio is 11.74, which is 30% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.48, compared to a current price of €0.25 — trading 48% below its estimated fair value. The current Cash Ratio is 11.74, which is 30% above median its 10-year median of 9.00 and 300.7% above the Biotechnology industry median of 2.93. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Cash Ratio is 11.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.25 is trading 48% below its estimated GF Value™ of €0.48.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
Cash Ratio: 11.74 (30% above median its 10-year median of 9.00)
GF Value™: €0.48 vs. price of €0.25 (48% below fair value)
Industry Position: 300.7% above the Biotechnology median (#221 of 1384)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for FRA:5VB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
